Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform ...
PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...
The performance of the proposed pipeline achieved an overall accuracy of 81%, precision of 79%, recall of 79%, F1-score of 78%, and a Matthews Correlation Coefficient (MCC) of 0.57 using the ...